RenovoRx Inc (RNXT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.31+1.55%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RNXT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 2.0 | 1.1 | 0.0 | — | — | — | — |
| Total Revenues | 2.0 | 1.1 | 0.0 | — | — | — | — |
| Cost of Revenues | 0.3 | 0.3 | — | — | — | — | — |
| Gross Profit | 1.7 | 0.8 | 0.0 | — | — | — | — |
| Operating Expenses & Income | |||||||
| Selling, General & Admin | 9.6 | 7.0 | 5.0 | 5.7 | — | — | — |
| R&D Expenses | 5.6 | 6.3 | 6.0 | 5.7 | 4.3 | 3.0 | 2.4 |
| Operating Income | (13.5) | (12.5) | (11.0) | (11.4) | (10.0) | (5.7) | (3.2) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 1.3 | 1.3 | 2.2 | 1.2 | 0.1 | (0.7) | (0.6) |
| EBT, Incl. Unusual Items | — | (11.2) | — | — | — | — | — |
| Income Tax Expense | — | 0.0 | — | — | — | — | — |
| Net Income | |||||||
| Net Income | (12.3) | (11.2) | (8.8) | (10.2) | (9.9) | (6.3) | (3.8) |
| Per Share | |||||||
| Basic EPS | (0.26) | (0.32) | (0.40) | (0.99) | (1.09) | (1.21) | — |
| Diluted EPS | (0.26) | (0.32) | (0.40) | (0.99) | (1.09) | — | — |
| Revenue per Share | 0.04 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 47.3 | 35.3 | 22.3 | 10.3 | 9.1 | 5.2 | — |
| Diluted Weighted Avg Shares | 47.3 | 35.3 | 22.3 | 10.3 | 9.1 | — | — |
| Supplemental | |||||||
| EBITDA | — | (10.5) | — | — | — | — | — |
| EBIT | (13.5) | (12.5) | (11.0) | (11.4) | (10.0) | (5.7) | (3.2) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.